The Global Antibiotic Research and Development Partnership and Indian biopharmaceutical company Bugworks Research Inc. announced an agreement today to accelerate development of a broad-spectrum antibiotic compound for multidrug-resistant bacterial infections.
The compound, BWC0977, has shown the potential to treat patients with serious infections caused by pathogens such as Acinetobacter baumannii and Klebsiella pneumoniae, which are frequently resistant to multiple classes of antibiotics and have become increasingly difficult to treat. A phase 1 trial, supported by GARDP and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), is currently underway in Australia.

Under the agreement, GARDP will provide up to $20 million in funding to further develop the compound, help advance it through phase 2 and phase 3 studies, and work with Bugworks on commercialization. If those studies provide proof of safety and efficacy, and the drug is approved, Bugworks will launch BWC0977 in the United States, European Union, Japan, and China, while GARDP will obtain commercialization and manufacturing rights in 148 countries, including nearly all low- and middle-income countries.
"We are thrilled to strengthen our ongoing partnership with GARDP to accelerate the clinical development of BWC0977 and deliver a truly differentiated broad-spectrum drug that can tackle the toughest drug-resistant superbugs," Anand Anandkumar, PhD, co-founder and CEO of Bugworks, said in a joint press release.
"We are delighted to be able to accelerate the development of this promising antibiotic compound, by supporting clinical and pharmaceutical development activities, with the hope of getting it to patients where it is most needed," said GARDP executive director Manica Balasegaram, MRCP, MSc.
Bugworks and GARDP said one of their priorities is to ensure rapid access and appropriate use of the compound, once approved, in India, South Africa, and other high-burden countries, where access to new antibiotics is often limited.